Journal
EXPERT REVIEW OF PROTEOMICS
Volume 12, Issue 3, Pages 235-253Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14789450.2015.1042867
Keywords
biomarkers; clinical proteomics; degradomics; ERLIC; glycoproteomics; LC-MS; phosphoproteomics; PTM; quantification
Categories
Funding
- Ministerium fur Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Deutsche Forschungsgemeinschaft (DFG) [ZA 639/4-1]
Ask authors/readers for more resources
Mass spectrometry-based proteomics has considerably extended our knowledge about the occurrence and dynamics of protein post-translational modifications (PTMs). So far, quantitative proteomics has been mainly used to study PTM regulation in cell culture models, providing new insights into the role of aberrant PTM patterns in human disease. However, continuous technological and methodical developments have paved the way for an increasing number of PTM-specific proteomic studies using clinical samples, often limited in sample amount. Thus, quantitative proteomics holds a great potential to discover, validate and accurately quantify biomarkers in body fluids and primary tissues. A major effort will be to improve the complete integration of robust but sensitive proteomics technology to clinical environments. Here, we discuss PTMs that are relevant for clinical research, with a focus on phosphorylation, glycosylation and proteolytic cleavage; furthermore, we give an overview on the current developments and novel findings in mass spectrometry-based PTM research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available